RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression

[1]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[2]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[3]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[4]  Jeffrey R. Jackson,et al.  Targeted anti-mitotic therapies: can we improve on tubulin agents? , 2007, Nature Reviews Cancer.

[5]  Qing Jiang,et al.  Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.

[6]  Takeshi Ono,et al.  Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5‐fluorouracil and docetaxel in head and neck squamous cell carcinoma , 2006, Cancer science.

[7]  Anna Frolov,et al.  Targeting Aurora kinases for the treatment of prostate cancer. , 2006, Cancer research.

[8]  M. Ozsahin,et al.  The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications , 2006, Radiation oncology.

[9]  P. Chieffi,et al.  Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation , 2006, The Prostate.

[10]  N. Georgopapadakou,et al.  Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  J. Au,et al.  Evaluation of Combination Chemotherapy , 2004, Clinical Cancer Research.

[12]  F. Sarkar,et al.  Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. , 2004, Molecular cancer therapeutics.

[13]  W. Pardridge,et al.  Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.

[14]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[15]  G. Pihan,et al.  Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. , 2003, Cancer research.

[16]  C. Arteaga,et al.  The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. , 2003, Seminars in oncology.

[17]  V. Srikantan,et al.  HEPSIN inhibits cell growth/invasion in prostate cancer cells. , 2002, Cancer research.

[18]  Stefania Staibano,et al.  Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  L. Mastronardi,et al.  Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas , 2001, BMC Cancer.

[20]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Wu,et al.  Characterization of novel inhibitors of cyclin-dependent kinases. , 1999, Biochemical and biophysical research communications.

[22]  D. Osoba,et al.  Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[24]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[25]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.